{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22.1","upperLimit":"63.4","value":"41.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"description":"Objective response will be determined according to RECIST 1.1 and as per IRC. Objective response was defined as number of participants with either a confirmed complete response (CR) or partial response (PR) from first administration of study treatment to first observation of progressive disease (PD) .CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 500 milligram (mg) of tepotinib once daily in cycles of 21-day duration until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.","id":"OG000","title":"Part 1: Cohort B: MET Amplification"}],"paramType":"NUMBER","populationDescription":"Safety Analysis Set included all participants in Cohort B who were administered at least 1 dose of tepotinib, including participants with a MET Amplification.","reportingStatus":"POSTED","timeFrame":"Time from first treatment up to data cutoff (approximately Month 66)","title":"Part 1: Cohort B: Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 as Assessed by Independent Review Committee (IRC)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}